SEC Comment Letter 0000000000-25-000596 to Enveric Biosciences, Inc. (ENVB)
Enveric Biosciences, Inc.
Date: Jan. 21, 2025 · CIK: 0000890821 · Accession: 0000000000-25-000596
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-284277
Letter
January 21, 2025 Joseph Tucker Chief Executive Officer Enveric Biosciences, Inc. 4851 Tamiami Trail N, Suite 200 Naples, FL 34103 Re:Enveric Biosciences, Inc. Registration Statement on Form S-1 Filed January 14, 2025 File No. 333-284277 Dear Joseph Tucker: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Brad Wyatt, Esq.
Show Raw Text
January 21, 2025
Joseph Tucker
Chief Executive Officer
Enveric Biosciences, Inc.
4851 Tamiami Trail N, Suite 200
Naples, FL 34103
Re:Enveric Biosciences, Inc.
Registration Statement on Form S-1
Filed January 14, 2025
File No. 333-284277
Dear Joseph Tucker:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Brad Wyatt, Esq.